Insilico Medicine to showcase results of generative biology target ID system

Insilico Medicine to showcase results of generative biology target ID system

Insilico Medicine, a biotechnology company developing end-to-end drug discovery pipelines utilizing the next-generation artificial intelligence, to present new results of its generative biology pipeline resulting in novel targets in liver disease. The company will showcase the results of the first experimental validation of its generative biology target ID system at CTIC on the 12th of January, 2020 and at Biotech Showcase, 13th of January, 2020. For the first time, we will present the results of our generative biology pipeline resulting in novel targets for liver disease during the JP Morgan. This is a major milestone for us, and we are happy to continue making history in AI-powered biomedicine." Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine You can also meet Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine at FierceBiotech Executive Breakfast on the 14 th of January, 2020. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More